Related Experiment Video

Updated: Jul 12, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Timosaponin A1 exerts antitumor effect against osteosarcoma by targeting JAK2/STAT3 signaling pathway

Jia Shi1, Yixuan Xu1, Tongtong Liu1

  • 1Department of Orthopedics, Shanghai Bone Tumor Institution, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, 100 Haining Street, Shanghai 200080, China.

The International Journal of Biochemistry & Cell Biology
|July 9, 2026
PubMed

Insights

Timosaponin A1 (TA1) effectively targets the IL-6/JAK2/STAT3 pathway in osteosarcoma. This natural compound inhibits tumor growth, migration, and invasion, showing promise as a novel therapeutic agent for this aggressive bone cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Osteosarcoma is an aggressive bone cancer with poor response to chemotherapy.
  • Aberrant STAT3 activation, via the IL-6/JAK2/STAT3 axis, is common in osteosarcoma and linked to poor outcomes.
  • Targeting STAT3 is a promising therapeutic strategy for osteosarcoma.

Purpose of the Study:

  • To investigate the potential of Timosaponin A1 (TA1) as a therapeutic agent for osteosarcoma.
  • To elucidate the mechanism by which TA1 affects osteosarcoma cells, focusing on the JAK2/STAT3 signaling pathway.

Main Methods:

  • In vitro studies using osteosarcoma cell lines to assess TA1's effects on cell cycle, apoptosis, migration, and invasion.
  • Biochemical assays to determine TA1's direct binding to JAK2 and its impact on STAT3 phosphorylation and nuclear translocation.
  • In vivo studies using an orthotopic tibial osteosarcoma xenograft mouse model to evaluate TA1's therapeutic efficacy.

Main Results:

  • TA1 suppressed osteosarcoma cell proliferation, induced cell-cycle arrest and apoptosis, and inhibited migration and invasion.
  • TA1 directly bound to JAK2, inhibiting STAT3 transcriptional activity and reducing JAK2/STAT3 phosphorylation.
  • TA1 blocked IL-6-induced STAT3 phosphorylation and nuclear translocation; STAT3 knockdown attenuated TA1's effects.
  • TA1 demonstrated significant antitumor effects in an in vivo osteosarcoma xenograft model.

Conclusions:

  • TA1 effectively suppresses osteosarcoma malignancy by inhibiting the JAK2/STAT3 signaling pathway.
  • TA1 exhibits potent antitumor activity through STAT3-dependent mechanisms.
  • TA1 represents a promising therapeutic candidate for osteosarcoma treatment.
Keywords:
IL-6/JAK2/STAT3 signalingOsteosarcomaSTAT3Timosaponin A1

More Related Videos

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...